A major challenge in the translation and commercialization of nanomaterials in medicine is the development of adequate pharmaceutical production processes that work equally well at large scale as at lab scale as (1,2). While several marketed pharmaceutical products employ nanotechnology, very little is publicly known about production processes and the translation from research to commercial scale (3). Continuous processes are often investigated (2,4,5), as they are considered easy to scale and more efficient, allow for simple process monitoring, and typically lead to less batch-to-batch variation. Although continuous nanoparticle precipitation methods—sometimes called flash nanoprecipitation—exist (5–7), in general, they are not suitable to produce nanoparticles of hydrophobic polymers and hydrophilic cargos. Such systems are often produced using the double emulsion method (8): the hydrophilic drug is dissolved in water and emulsified into a non- or partially miscible solvent containing the polymer. This two-phase system is further emulsified into an outer aqueous phase containing a stabilizer. The solvent is subsequently removed and the polymer precipitates to form nanoparticles around the hydrophilic drug. The critical steps of emulsification and solvent removal are typically done with batch processing (9). We previously reported the use of a focused ultrasound transducer coupled with a flow-through cell for a contact-free and scalable emulsification capable of continuous processing (9). The logical next step would be to also adapt the solvent evaporation to a continuous process, for example, by spray drying.